Upholding the efficacy of
our SARS-CoV-2 assays
Ongoing vigilance to assess potential impacts of SARS- CoV-2 mutations and variants to PCR assays
LGC, Biosearch Technologies is committed to maintaining the accuracy of our SARS-CoV-2 Real-Time and End-Point RT-PCR Test, and SARS-CoV-2 Variant ValuPanel assays through a variety of risk mitigation protocols:
Conducting fortnightly screens of our assays against the GISAID sequences for any adverse mutations.
Assay functionality testing measures staged for emerging variants of concern.
Assessment of alternative diagnostic assay combinations and preparing them for deployment, if the need arises.
Stay up to date on how we’re monitoring variants
Resource title
Publish date
- Ensuring our diagnostic assays detect the Omicron variant 09 December 2021
- Technical bulletin: SARS-CoV-2 mutation analysis and investigation 14 October 2021
- How do SARS-CoV-2 variants affect PCR assays for COVID-19 testing 04 May 2021
- Technical Bulletin: SARS-CoV-2 variants and mutations 15 April 2021
